Does bosentan prevent overcirculation-induced experimental pulmonary arterial hypertension?
Bosentan completely prevents overcirculation-induced pulmonary arterial hypertension in an experimental model, suggesting a causal role for the pulmonary ET-1 system.
Experimental overcirculation-induced pulmonary arterial hypertension appears to be causally related to an activation of the pulmonary ET-1 system and as such is completely prevented by the dual endothelin receptor antagonist bosentan.
Rondelet et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: